Ozmosi | Aminosalicylic acid Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Aminosalicylic acid

Alternative Names: aminosalicylic acid, paser, parasal, neopasalate
Clinical Status: Inactive
Latest Update: 2026-01-09
Latest Update Note: News Article

Product Description

Aminosalicylic Acid is an analog of para-aminobenzoic acid (PABA) with antitubercular activity. Aminosalicylic acid exerts its bacteriostatic activity against Mycobacterium tuberculosis by competing with PABA for enzymes involved in folate synthesis, thereby suppressing growth and reproduction of M. tuberculosis, eventually leading to cell death. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/4-Aminosalicylic-acid)

Mechanisms of Action: Folic Acid Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Austria | Bangladesh | Belgium | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Norway | Pakistan | Poland | Portugal | Russia | Slovakia | Slovenia | South Africa | Spain | Sweden | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated